Literature DB >> 3532763

Pneumococcal carriage and type-specific antibody. Failure of a 14-valent vaccine to reduce carriage in healthy children.

R M Douglas, D Hansman, H B Miles, J C Paton.   

Abstract

No consistent effect on nasal carriage rates of Streptococcus pneumoniae belonging to vaccine types was observed during a randomized, controlled trial of a 14-valent pneumococcal vaccine, which included 1273 Australian children aged 6 to 54 months. Nasal carriage of S pneumoniae was associated with a significantly elevated homotypic serum antibody concentration for types 18C, 19F, and 23F, but not for types 6A and 14 (these five types are the most important causes of pneumococcal infections in children). Upper respiratory tract carriage seems to play an important role in natural acquisition of antibody to some but not all pneumococcal serotypes. These findings help to explain why pneumococcal vaccine fails to protect young children from acute otitis media.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3532763     DOI: 10.1001/archpedi.1986.02140250109044

Source DB:  PubMed          Journal:  Am J Dis Child        ISSN: 0002-922X


  14 in total

Review 1.  Mucosal immunology of vaccines against pathogenic nasopharyngeal bacteria.

Authors:  Q Zhang; A Finn
Journal:  J Clin Pathol       Date:  2004-10       Impact factor: 3.411

2.  Pneumococcal nasopharyngeal carriage following reduced doses of a 7-valent pneumococcal conjugate vaccine and a 23-valent pneumococcal polysaccharide vaccine booster.

Authors:  F M Russell; J R Carapetis; C Satzke; L Tikoduadua; L Waqatakirewa; R Chandra; A Seduadua; S Oftadeh; Y B Cheung; G L Gilbert; E K Mulholland
Journal:  Clin Vaccine Immunol       Date:  2010-10-13

Review 3.  Periodic health examination, 1991 update: 2. Administration of pneumococcal vaccine. Canadian Task Force on the Periodic Health Examination.

Authors: 
Journal:  CMAJ       Date:  1991-03-15       Impact factor: 8.262

4.  Antibiotic resistance in common acute respiratory pathogens.

Authors:  P Venkatesan; J A Innes
Journal:  Thorax       Date:  1995-05       Impact factor: 9.139

Review 5.  Immunogenicity and immunochemistry of Streptococcus pneumoniae capsular polysaccharides.

Authors:  J E van Dam; A Fleer; H Snippe
Journal:  Antonie Van Leeuwenhoek       Date:  1990-06       Impact factor: 2.271

6.  Persistence of infection in mice inoculated intranasally with Cryptococcus neoformans.

Authors:  D A Anderson; H M Sagha
Journal:  Mycopathologia       Date:  1988-12       Impact factor: 2.574

7.  Vaccination against colonizing bacteria with multiple serotypes.

Authors:  M Lipsitch
Journal:  Proc Natl Acad Sci U S A       Date:  1997-06-10       Impact factor: 11.205

8.  Safety and immunogenicity of the 23-valent pneumococcal polysaccharide vaccine at 12 months of age, following one, two, or three doses of the 7-valent pneumococcal conjugate vaccine in infancy.

Authors:  F M Russell; P V Licciardi; A Balloch; V Biaukula; L Tikoduadua; J R Carapetis; J Nelson; A W J Jenney; L Waqatakirewa; S Colquhoun; Y B Cheung; M L K Tang; E K Mulholland
Journal:  Vaccine       Date:  2010-03-01       Impact factor: 3.641

Review 9.  Should patients positive for HIV infection receive pneumococcal vaccine?

Authors:  A Jain; S Jain; V Gant
Journal:  BMJ       Date:  1995-04-22

10.  Long-term impact of pneumococcal polysaccharide vaccination on nasopharyngeal carriage in children previously vaccinated with various pneumococcal conjugate vaccine regimes.

Authors:  Laura K Boelsen; Eileen M Dunne; Karen E Lamb; Kathryn Bright; Yin Bun Cheung; Lisi Tikoduadua; Fiona M Russell; E Kim Mulholland; Paul V Licciardi; Catherine Satzke
Journal:  Vaccine       Date:  2015-07-29       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.